July 11 (Reuters) - AstraZeneca Plc AZN.L
* Tagrisso approved by Health Canada as treatment for
patients with locally advanced or metastatic EGFR T790M
mutation-positive non-small cell lung cancer
Source text for Eikon: ID:nCNWMc1QSa
Further company coverage: AZN.L
(Bengaluru Newsroom: +1 646 223 8780)